Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinal pigment epithelium (RPE) replacement refers to therapeutic strategies aimed at restoring or substituting the RPE cell layer in the retina, primarily to treat degenerative retinal diseases such as age-related macular degeneration (AMD) and Stargardt disease. The RPE is a single layer of pigmented cells essential for maintaining retinal homeostasis and supporting photoreceptor function. RPE replacement involves transplanting iPSC- or ESC-derived RPE cells to replace damaged or dysfunctional native RPE, thereby restoring barrier function, phagocytosis, light absorption, visual cycle support, and metabolic support.
Replacement of dysfunctional or degenerated retinal pigment epithelium cells with healthy cells derived from iPSC or ESC, aiming to restore the structural and functional integrity of the outer blood-retina barrier and support photoreceptor survival.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinal pigment epithelium replacement.